A new drug to slow the progression of Alzheimer’s disease is bringing renewed hope to patients battling the devastating diagnosis. The U.S. Food and Drug Administration approved Eli Lilly and Company’s drug donanemab, under the name brand Kisunla in early July. The once a month IV infusion works by targeting amyloid in the brain.